Abstract
Carbon monoxide (CO) mediates many of the biological effects that are attributed to heme oxygenase (HO), the enzyme responsible for CO production in mammals. Antioxidant and anti-inflammatory activities of HO-1, the inducible isoform of heme oxygenase, have been demonstrated in a variety of disease models and a therapeutic exploitation of this pathway is currently under scrutiny. In this context, the liberation of CO from CO-releasing molecules (CO-RMs) is extremely attractive as these compounds may form the basis of a new class of pharmaceuticals. Recent investigations indicate that HO-1 and CO modulate important processes in chronic inflammation; these include the control of immune responses, the production of inflammatory mediators and the mitigation of cartilage or bone destruction. As HO-1 is highly expressed in the joint tissues of patients affected by arthritic diseases, it is plausible to suggest that this pathway may play a protective role against joint degenerative diseases. Studies aimed at identifying the signaling pathways responsive to endogenous CO and CO-RMs in rheumatoid arthritis and other inflammatory states are currently in progress. This research will help to elucidate the molecular mechanisms underlying the pharmacological effects of CO-RMs and may lead to the development of novel therapeutic strategies for the treatment of acute and chronic inflammatory conditions.
Current Pharmaceutical Design
Title: Carbon Monoxide-Releasing Molecules: A Pharmacological Expedient to Counteract Inflammation
Volume: 14 Issue: 5
Author(s): Maria Jose Alcaraz, Maria Isabel Guillen, Maria Luisa Ferrandiz, Javier Megias and Roberto Motterlini
Affiliation:
Abstract: Carbon monoxide (CO) mediates many of the biological effects that are attributed to heme oxygenase (HO), the enzyme responsible for CO production in mammals. Antioxidant and anti-inflammatory activities of HO-1, the inducible isoform of heme oxygenase, have been demonstrated in a variety of disease models and a therapeutic exploitation of this pathway is currently under scrutiny. In this context, the liberation of CO from CO-releasing molecules (CO-RMs) is extremely attractive as these compounds may form the basis of a new class of pharmaceuticals. Recent investigations indicate that HO-1 and CO modulate important processes in chronic inflammation; these include the control of immune responses, the production of inflammatory mediators and the mitigation of cartilage or bone destruction. As HO-1 is highly expressed in the joint tissues of patients affected by arthritic diseases, it is plausible to suggest that this pathway may play a protective role against joint degenerative diseases. Studies aimed at identifying the signaling pathways responsive to endogenous CO and CO-RMs in rheumatoid arthritis and other inflammatory states are currently in progress. This research will help to elucidate the molecular mechanisms underlying the pharmacological effects of CO-RMs and may lead to the development of novel therapeutic strategies for the treatment of acute and chronic inflammatory conditions.
Export Options
About this article
Cite this article as:
Alcaraz Jose Maria, Guillen Isabel Maria, Ferrandiz Luisa Maria, Megias Javier and Motterlini Roberto, Carbon Monoxide-Releasing Molecules: A Pharmacological Expedient to Counteract Inflammation, Current Pharmaceutical Design 2008; 14 (5) . https://dx.doi.org/10.2174/138161208783597362
DOI https://dx.doi.org/10.2174/138161208783597362 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Platelet-neutrophil Interactions as a Target for Prevention and Treatment of Transfusion- related Acute Lung Injury
Current Pharmaceutical Design IL-1 as a target in inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Biologics for the Treatment of Juvenile Idiopathic Arthritis
Current Medicinal Chemistry Subject Index To Volume 12
Current Pharmaceutical Design Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease
Current Topics in Medicinal Chemistry Peripheral Anti-nociceptive and Anti-inflammatory Effect of Oleanolic Acid in a Rat Model of Osteoarthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Anti-Interleukin-6 Receptor Antibody Therapy in Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Drug-Glycosidation and Drug Development
Mini-Reviews in Medicinal Chemistry Effects of Plants and Isolates of Celastraceae Family on Cancer Pathways
Anti-Cancer Agents in Medicinal Chemistry ‘Toll’ Gates for Future Immunotherapy
Current Pharmaceutical Design The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy
Current Cancer Drug Targets Recent Patents Therapeutic Agents for Cancer
Recent Patents on Anti-Cancer Drug Discovery The Role of C-Reactive Protein in Atherosclerotic Cardiovascular Disease: An Overview
Current Vascular Pharmacology Anti-inflammatory Property of AMP-activated Protein Kinase
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry COX-2 Selective Inhibitors in the Treatment of Arthritis: A Rheumatologist Perspective
Current Topics in Medicinal Chemistry Synergistic Effect of Curcumin: A Review
Current Bioactive Compounds Recent Progress in the Discovery of Novel Glucocorticoid Receptor Modulators
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Bone and Immune System Cross-Talk (Guest Editors: Nadia Rucci and Hiroshi Takayanagi)]
Inflammation & Allergy - Drug Targets (Discontinued)